Corcept Therapeutics

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Society, International Society, Health, Naltrexone, Knowledge, American Journal, DSM-IV codes, Substance abuse, Opioid use disorder, American College, Addiction medicine, CFO, Addiction, Therapy, GSK plc, American Medical Association, Corcept Therapeutics, OTCQB, Principal investigator, Alzheimer's disease, Neuroscience, Parkinson's disease, Doctor of Philosophy, Merck, Journal, OUD, NACDA, Research, JAMA, Obesity, Anxiety, American Psychiatric Association, Pharmaceutical industry

ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.

Key Points: 
  • ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.
  • Dr. DeVarney is the President, Chief Operating Officer, and a Director of Titan Pharmaceuticals, Inc.  She was previously Titan’s Chief Scientific Officer and has been with the company since 2007.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “We are honored and excited to welcome Dr. DeVarney to the BioCorRx Pharmaceuticals board.
  • I look forward to working closely with the management team to bring BICX104 to market.”

Sterne Kessler Secures Non-Infringement Win for Teva Pharmaceuticals

Retrieved on: 
Friday, January 5, 2024
Orange Book, Teva, Syndrome, FDA, The Orange Book, Therapy, Cushing's syndrome, Mifepristone, Type, Corcept Therapeutics, Teva Pharmaceuticals, Patient, Prediabetes, Generic drug

WASHINGTON, Jan. 5, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox secured a victory on behalf of Teva Pharmaceuticals in the U.S. Court District Court for the District of New Jersey in a case involving a patent-infringement suit filed by Corcept Therapeutics.

Key Points: 
  • WASHINGTON, Jan. 5, 2024 /PRNewswire/ -- Sterne, Kessler, Goldstein & Fox secured a victory on behalf of Teva Pharmaceuticals in the U.S. Court District Court for the District of New Jersey in a case involving a patent-infringement suit filed by Corcept Therapeutics.
  • On December 29, 2023, the district court held that Teva does not infringe the two patents asserted at trial, finding that Corcept had failed to show that direct infringement is likely or that Teva's label would induce infringement.
  • Teva Pharmaceuticals USA, Inc. is a leading manufacturer of generic and proprietary drug products.
  • Corcept Therapeutics, Inc., the holder of the Korlym NDA, filed a Hatch-Waxman lawsuit against Teva alleging infringement of two patents listed in the Orange Book for Korlym.

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director

Retrieved on: 
Monday, December 4, 2023
Metabolism, Breast cancer, Messenger, Medical director, Therapy, Clinical trial, Mathematics, University, COVID-19, Corcept Therapeutics, Silicon, Patient

SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the appointment of Dr. Arezoo Mirad as Senior Medical Director.

Key Points: 
  • SEATTLE, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced the appointment of Dr. Arezoo Mirad as Senior Medical Director.
  • In this role she acted as the lead medical monitor for global phase 2 and 3 registrational oncology clinical trials, led global site selection, and oversaw regulatory interactions.
  • Dr. Mirad previously served as Medical Director for Alkermes, a fully integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology.
  • “(Z)-endoxifen is a compelling asset that I believe will meaningfully improve outcomes for breast cancer patients,” remarked Dr. Mirad.

Corcept Appoints Monica Tellado as President, Emerging Markets

Retrieved on: 
Wednesday, November 1, 2023
Union of Sales and Marketing Professionals, Therapy, Heel, HIV, Commercial Operating System, Gilead Sciences, Metabolism, NASH, ALS, Fatty liver disease, Neurology, Hepatology, Patient, Emerging market, Marketing, CORT, Pharmaceutical industry, Medical device, MD, Corcept Therapeutics

At Corcept, Ms. Tellado will serve as the global commercial lead for therapeutics in metabolism and neurology.

Key Points: 
  • At Corcept, Ms. Tellado will serve as the global commercial lead for therapeutics in metabolism and neurology.
  • “We are thrilled to welcome Monica to Corcept,” said Dr. Belanoff.
  • “Corcept is a truly innovative company with a collaborative approach to unlocking the potential of cortisol modulation.
  • I’m delighted to join the organization at such an exciting time in its evolution,” said Ms. Tellado.

Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

Retrieved on: 
Thursday, October 19, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Hyperoxaluria, Heidelberg University School of Medicine, Proctor, Endocrinology, Nephrology, Publication, Inflammation, Metabolism, Corcept Therapeutics, Baylor College of Medicine, Medicine, Amgen, Internal medicine, Neurology, Corporation, University, NDA, Safety, Therapy, Patient, BLA, Baylor University, Pharmaceutical industry, Management, Omeros

Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer.
  • In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics.
  • “We are very pleased to welcome Andreas to Omeros’ leadership team,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros.
  • He joins Omeros from Federation Bio where, as chief medical officer, he led all clinical activities with a focus on hyperoxaluria and immuno-oncology.

eFFECTOR Therapeutics Appoints Caroline Loewy to Board of Directors

Retrieved on: 
Monday, September 11, 2023
Morgan Stanley, Therapy, University, Education, Corcept Therapeutics, Berkeley, Biotechnology, Audit committee, Cancer, Research, Effector, Prudential Securities, Organization, Acquisition, Carnegie Mellon University, Global Genes, Allergan, Inc., Pharmaceutical industry, Management

Concurrent with Ms. Loewy’s appointment, current Board member John Smither has resigned from the Board.

Key Points: 
  • Concurrent with Ms. Loewy’s appointment, current Board member John Smither has resigned from the Board.
  • “We are tremendously fortunate to welcome Caroline given her extensive experience as an executive and board member at multiple biopharmaceutical companies,” remarked Steve Worland, Ph.D., president and chief executive officer of eFFECTOR.
  • At the same time, on behalf of the entire eFFECTOR team and the Board, I would like to express our utmost gratitude to John for his invaluable contributions to eFFECTOR.”
    “I look forward to working with the management team and other Board members at eFFECTOR,” said Ms. Loewy.
  • Ms. Loewy also currently sits on the board of CymaBay Therapeutics, Inc., PhaseBio Pharmaceuticals, Inc. and Phoenix Biotech Acquisition Corp. Ms. Loewy holds a B.A.

Jazz Pharmaceuticals Announces Key Update to Leadership Team

Retrieved on: 
Tuesday, September 12, 2023
Mathematics, Corcept Therapeutics, Vanderbilt University, Columbia Business School, Eli Lilly, GRAIL, Jazz Pharmaceuticals, Acquisition, Novartis, Patient, CFO, Therapy, Nightclub, Management, Jazz

DUBLIN, Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023. Dan Swisher has notified the company of his intention to retire from his position as President and COO after five and a half years of significant contribution towards establishing Jazz as an innovative biopharmaceutical company. Mr. Swisher will continue in a strategic advisor role to assist the Company in an orderly transition through March 2024. The Company will promptly initiate an external search for a Chief Financial Officer.

Key Points: 
  • DUBLIN, Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023.
  • Mr. Swisher will continue in a strategic advisor role to assist the Company in an orderly transition through March 2024.
  • I'm excited to welcome Renée to this key role, which is a reflection of her strategic leadership, extensive industry experience and embodiment of Jazz's culture, values and objectives.
  • "It is a privilege to work with such a talented Jazz team that is incredibly passionate, not only about transforming our business, but also the lives of patients and their families," said Renée Galá, Executive Vice President & Chief Financial Officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Announces Key Update to Leadership Team

Retrieved on: 
Tuesday, September 12, 2023
Mathematics, Corcept Therapeutics, Vanderbilt University, Columbia Business School, Eli Lilly, GRAIL, Jazz Pharmaceuticals, Acquisition, Novartis, Patient, CFO, Therapy, Nightclub, Management, Jazz

DUBLIN, Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023. Dan Swisher has notified the company of his intention to retire from his position as President and COO after five and a half years of significant contribution towards establishing Jazz as an innovative biopharmaceutical company. Mr. Swisher will continue in a strategic advisor role to assist the Company in an orderly transition through March 2024. The Company will promptly initiate an external search for a Chief Financial Officer.

Key Points: 
  • DUBLIN, Sept. 12, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023.
  • Mr. Swisher will continue in a strategic advisor role to assist the Company in an orderly transition through March 2024.
  • I'm excited to welcome Renée to this key role, which is a reflection of her strategic leadership, extensive industry experience and embodiment of Jazz's culture, values and objectives.
  • "It is a privilege to work with such a talented Jazz team that is incredibly passionate, not only about transforming our business, but also the lives of patients and their families," said Renée Galá, Executive Vice President & Chief Financial Officer of Jazz Pharmaceuticals.

Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover

Retrieved on: 
Tuesday, August 8, 2023
Temple University, Drug discovery, Head, University of Bristol, Merck, Commercial Operating System, Biotechnology Innovation Organization, Otsuka Pharmaceutical, BIO, University, Ōtsuka, GW, Honours degree, GW Pharmaceuticals, Genetic distance, Corcept Therapeutics, Organization, UCB, Villalba v Merrill Lynch & Co Inc, Cannabidiol, Mazda North American Operations, Drexel University, Epilepsy, Neuroscience, INSEAD, Justin, Roivant Sciences, Therapy, Doctor of Philosophy, Sale, Defense Innovation Board, DSM-IV codes, Jazz Pharmaceuticals, University of Edinburgh, Pharmaceutical industry, Xenon

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.

Key Points: 
  • VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.
  • Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “On behalf of our Board of Directors, I am delighted to welcome Gillian and Justin to our Board.
  • Gillian brings a vast knowledge of commercializing novel medicines and leading successful neuroscience franchises at large pharmaceutical companies.
  • Mr. Gover currently serves on the Board of Directors for CURE Epilepsy and Rady Children’s Institute for Genomic Medicine.

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, August 2, 2023
Journal of Clinical Oncology, Doctor of Pharmacy, Depression, University, Prevalence, NASH, Diabetes, Anxiety, NDA, Syndrome, Neck, Corcept Therapeutics, PIN, Metabolism, MD, Investment, Physician, Cushing's syndrome, Patient, CORT, Liver, Growth, Ageing, American Association of Clinical Endocrinologists, Irritability, ALS, Fatigue, Prostate cancer, Pharmaceutical industry, Cryptocurrency

Corcept’s second quarter 2023 revenue was $117.7 million, compared to $103.4 million in the second quarter of 2022.

Key Points: 
  • Corcept’s second quarter 2023 revenue was $117.7 million, compared to $103.4 million in the second quarter of 2022.
  • Second quarter operating expenses were $88.1 million, compared to $72.0 million in the second quarter of 2022, due to increased spending on our development programs and to support the expansion of our clinical development and commercial teams.
  • Net income was $27.5 million in the second quarter of 2023 compared to $27.4 million in the same period last year.
  • In April 2023, Corcept purchased 6.6 million shares of its common stock for $145.4 million.